An evaluation of tofacitinib for the treatment of psoriatic arthritis

References

• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77–i84.
   PubMed Web of Science ®Google Scholar
• Cella D, Wilson H, Shalhoub H, et al. Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis. J Patient-reported Outcomes. 2019;3(1):5.
   PubMedGoogle Scholar
• Lebwohl MG, Kavanaugh A, Armstrong AW, et al. Us perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (mapp) survey. Am J Clin Dermatol. 2016;17(1):87–97.
   PubMed Web of Science ®Google Scholar
• Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology. 2015;54(1):20–28.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):e871–e830.
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Marks JL, van der Heijde DM, et al. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: A cochrane systematic review. J Rheumatol Suppl. 2012;90:62–73.
   PubMedGoogle Scholar
• Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology. 2010;49(7):1367–1373.
   PubMed Web of Science ®Google Scholar
• Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008;67(6):855–859.
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64(6):859–864.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European league against rheumatism (eular) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Coates LC, Ritchlin CT, Kavanaugh AF. Grappa treatment recommendations: an update from the grappa 2013 annual meeting. J Rheumatol. 2014;41(6):1237–1239.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659.
   PubMed Web of Science ®Google Scholar
• Merola JF, Ogdie A. Seam-psa: seems like methotrexate works in psoriatic arthritis? Arthritis Rheumatol. 2019;71(7):1027–1029.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69(1):43–47.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Guerin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010;220(2):128–137.
   PubMed Web of Science ®Google Scholar
• Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: Four cases and recommendations for treatment. Br J Dermatol. 2009;161(4):964–966.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic tnf antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Directions Autoimmunity. 2010;11:180–210.
   PubMedGoogle Scholar
• Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the british society of rheumatology biologics register. Arthritis Res Ther. 2009;11(2):R52.
   PubMed Web of Science ®Google Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: A pde4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of janus kinase (jak) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. Jak-stat signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–546.
   PubMed Web of Science ®Google Scholar
• Lim CP, Cao X. Structure, function, and regulation of stat proteins. Mol Biosyst. 2006;2(11):536–550.
   PubMedGoogle Scholar
• Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting stat activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75(1):311–315.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid t cells in psoriatic arthritis. Clin Rheumatol. 2015;34(9):1571–1580.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the jak1/jak3 inhibitor, cp-690,550, in rat adjuvant-induced arthritis. J Inflam. 2010;7:41.
   Google Scholar
• de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627–634.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the jak stat kinase signalling system on the il-23/il-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76(10):e36.
   PubMed Web of Science ®Google Scholar
• Vafadari R, Quaedackers ME, Kho MM, et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. Transplantation. 2012;94(5):465–472.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–1493.e1482.
   PubMed Web of Science ®Google Scholar
• Krishnaswami S, Boy M, Chow V, et al. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a janus kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(2):83–88.
   PubMed Web of Science ®Google Scholar
• Cada DJ, Demaris K, Levien TL, et al. Tofacitinib. Hosp Pharm. 2013;48(5):413–424.
   PubMedGoogle Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of jak kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to tnf inhibitors. N Engl J Med. 2017;377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: Pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5(2):567–582.
   PubMed Web of Science ®Google Scholar
• Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242.
   PubMedGoogle Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase iii, randomised controlled trial: opal beyond. RMD Open. 2019;5(1):e000808.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from opal broaden-a phase iii study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase iib dose-ranging study of the oral jak inhibitor tofacitinib (cp-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheumatism. 2012;64(3):617–629.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (cp-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 2013;381(9865):451–460.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Panes J, Vermeire S, Lindsay JO, et al. Tofacitinib in patients with ulcerative colitis: Health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohn’s Colitis. 2018;12(2):145–156.
   Google Scholar
• Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase iii trials. Br J Dermatol. 2015;173(4):949–961.
   PubMed Web of Science ®Google Scholar
• Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-iii studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–850.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: A phase ii, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline c-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019.
   Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (cp-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase iii randomized radiographic study. Arthritis Rheumatism. 2013;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Ostergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised mri study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75(6):1024–1033.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a jak inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase iia trial of three dosage levels of cp-690,550 versus placebo. Arthritis Rheumatism. 2009;60(7):1895–1905.
   PubMed Web of Science ®Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Virtanen AT, Haikarainen T, Raivola J, et al. Selective jakinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32.
   Web of Science ®Google Scholar
• Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–2265.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837–852.
   PubMed Web of Science ®Google Scholar
• Verden A, Dimbil M, Kyle R, et al. Analysis of spontaneous postmarket case reports submitted to the fda regarding thromboembolic adverse events and jak inhibitors. Drug Saf. 2018;41(4):357–361.
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–2617.
   PubMed Web of Science ®Google Scholar
• Sonomoto K, Yamaoka K, Kubo S, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology. 2014;53(5):914–918.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Charles-Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: A pooled analysis across phase 3 and long-term extension studies. Arthritis Care Res (Hoboken). 2019.
   Google Scholar
• Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261–271.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 american college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32.
   PubMed Web of Science ®Google Scholar